Abivax S.a.
Clinical trials sponsored by Abivax S.a., explained in plain language.
Biotech developing treatments for inflammatory diseases and viral infections.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pill hopes to stop UC Flare-Ups in their tracks
Disease control OngoingThis phase 3 trial tests whether a daily pill called ABX464 (obefazimod) can help people with moderate-to-severe ulcerative colitis stay in remission. Over 1,100 participants who completed an earlier induction study will receive either 25 mg, 50 mg, or a placebo for 44 weeks. The…
Phase: PHASE3 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill shows promise for Long-Term ulcerative colitis control
Disease control OngoingThis study tests the long-term safety and effectiveness of an experimental drug called ABX464 in people with moderate to severe ulcerative colitis. Participants who previously improved on ABX464 in earlier studies will continue taking it daily for up to 54 months. Researchers wil…
Phase: PHASE2 • Sponsor: Abivax S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC